The Goldman Sachs Group Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Key Points

• Goldman Sachs raised Merck’s price target to $160 from $140 and maintained a “buy” rating, implying 5.39% upside from the prior close.
• Analyst sentiment is broadly positive, with 15 buy ratings and eight holds producing a “Moderate Buy” consensus and an average target of $144.10; Morgan Stanley and UBS set higher targets of $179 and $175, respectively.
• Merck shares rose 1.9% to $151.82 after the company exceeded quarterly earnings and revenue expectations, though investors still face valuation concerns and the risk of Keytruda losing exclusivity in 2028.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) had its price target lifted by analysts at The Goldman Sachs Group from $140.00 to $160.00 in a report issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. The Goldman Sachs Group's price target indicates a potential upside of 5.39% from the company's previous close.

A number of other analysts have also recently commented on the company. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $120.00 price target on shares of Merck & Co., Inc. in a research report on Monday, July 6th. JPMorgan Chase & Co. raised their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. Morgan Stanley raised shares of Merck & Co., Inc. from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $116.00 to $179.00 in a report on Thursday. CICC Research began coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an "outperform" rating and a $138.00 target price for the company. Finally, UBS Group lifted their price objective on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday. Fifteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $144.10.

Merck & Co., Inc. Stock Up 1.9%

NYSE:MRK traded up $2.83 during midday trading on Friday, reaching $151.82. 8,557,185 shares of the stock traded hands, compared to its average volume of 10,815,531. The business has a 50-day moving average of $127.43 and a two-hundred day moving average of $121.01. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a 12-month low of $77.58 and a 12-month high of $154.49. The stock has a market capitalization of $374.57 billion, a PE ratio of 121.46, a price-to-earnings-growth ratio of 6.56 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. During the same quarter last year, the firm earned $2.13 EPS. The business's quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 11,699 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the transaction, the executive vice president directly owned 110,167 shares of the company's stock, valued at $14,501,282.21. This trade represents a 9.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of the business's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares of the company's stock, valued at $6,073,631.14. This represents a 63.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock worth $29,977,783 in the last 90 days. 0.17% of the stock is owned by insiders.

Institutional Investors Weigh In On Merck & Co., Inc.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. D.A. Davidson & CO. increased its stake in Merck & Co., Inc. by 4.4% during the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company's stock worth $60,731,000 after acquiring an additional 24,576 shares during the last quarter. Pinnbrook Capital Management LP raised its position in Merck & Co., Inc. by 95.2% in the 4th quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company's stock worth $2,450,000 after purchasing an additional 11,355 shares during the period. Cibc World Market Inc. lifted its stake in Merck & Co., Inc. by 32.6% in the fourth quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company's stock worth $137,022,000 after purchasing an additional 320,143 shares during the last quarter. Handelsbanken Fonder AB boosted its position in shares of Merck & Co., Inc. by 13.9% during the fourth quarter. Handelsbanken Fonder AB now owns 1,843,042 shares of the company's stock valued at $193,999,000 after buying an additional 224,752 shares during the period. Finally, Panagora Asset Management Inc. lifted its stake in shares of Merck & Co., Inc. by 410.5% during the 4th quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company's stock worth $74,255,000 after acquiring an additional 567,249 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Phase 3 cancer-vaccine success: Merck and Moderna reported that their personalized mRNA vaccine, used with Merck’s Keytruda, improved recurrence-free and distant metastasis-free survival in high-risk melanoma patients versus Keytruda alone. It is the first positive late-stage result for an mRNA cancer vaccine and supports a potential regulatory filing aimed at approval as early as 2027. MRK/MRNA's Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Analyst support strengthened: Morgan Stanley upgraded MRK to overweight and raised its price target to $179, while UBS lifted its target to $175 with a buy rating. BMO also raised its target to $170 and maintained an outperform rating, reflecting greater confidence in Merck’s oncology opportunity. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Positive Sentiment: Pipeline diversification: Merck’s newer medicines, acquired assets and product launches are gaining traction and could help cushion revenue pressure when Keytruda loses exclusivity, expected in 2028. Can Merck's New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates elevated investor interest and potential near-term volatility, but it does not by itself change Merck’s fundamentals. Merck & Co., Inc. Target of Unusually High Options Trading
• Negative Sentiment: Valuation and patent risk: RBC downgraded MRK to sector perform with a $150 target, arguing that the stock’s sharp rally has produced an unusually high valuation for a company facing Keytruda’s loss of exclusivity in roughly two years. Jefferies separately moved the shares to hold. Merck’s Cancer-Vaccine Trial Results Surpassed Expectations – So, Why Did RBC Downgrade MRK Stock?
• Negative Sentiment: Execution remains ahead: The vaccine still requires regulatory approval, commercial launch and successful expansion beyond melanoma; analysts caution that the trial win alone does not yet offset the longer-term Keytruda revenue risk.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source